Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1998-1-28
pubmed:abstractText
To evaluate the safety and physiologic response of inhaled nitric oxide (NO) in patients with acute respiratory distress syndrome (ARDS). In addition, the effect of various doses of inhaled NO on clinical outcome parameters was assessed.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0090-3493
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
15-23
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9428538-Acute Disease, pubmed-meshheading:9428538-Administration, Inhalation, pubmed-meshheading:9428538-Adolescent, pubmed-meshheading:9428538-Adult, pubmed-meshheading:9428538-Dose-Response Relationship, Drug, pubmed-meshheading:9428538-Double-Blind Method, pubmed-meshheading:9428538-Female, pubmed-meshheading:9428538-Follow-Up Studies, pubmed-meshheading:9428538-Humans, pubmed-meshheading:9428538-Male, pubmed-meshheading:9428538-Middle Aged, pubmed-meshheading:9428538-Nitric Oxide, pubmed-meshheading:9428538-Prospective Studies, pubmed-meshheading:9428538-Reproducibility of Results, pubmed-meshheading:9428538-Respiration, pubmed-meshheading:9428538-Respiratory Distress Syndrome, Adult, pubmed-meshheading:9428538-Safety, pubmed-meshheading:9428538-Survival Rate, pubmed-meshheading:9428538-Time Factors, pubmed-meshheading:9428538-Treatment Outcome
pubmed:year
1998
pubmed:articleTitle
Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group.
pubmed:affiliation
University of Missouri, Columbia, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II